SHILPAMED — Shilpa Medicare Share News
0.000.00%
Last trade - 00:00- IN₹184.31bn
- IN₹189.99bn
- IN₹15.39bn
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026
Brief: Shilpa Medicare Ltd Says June-Quarter Consol Net Pat 1.01 Billion Rupees
Development And Supply Agreement With Orion Corporation
India's Shilpa Medicare rises after unit enters agreement with Orion Corporation
Brief: Shilpa Medicare's Unit Enters Settlement Agreement With Sartorius Stedim India For 90 Million Rupees
Brief: Shilpa Medicare Unit Intends To Make A Strategic Equity Partnership Of 30.4% In Gate2brain
Brief: Shilpa Medicare March-Quarter Consol Net PAT 1.08 Billion Rupees
Brief: Shilpa Medicare Says NCLT Approves Amalgamation Of Shilpa Therapeutics With Co
Brief: Shilpa Medicare Ltd Says Shilpa Biologicals And Steincares To Commercialize Biosimilar In Latin America
Brief: Shilpa Medicare Enters Agreement With NXI Therapeutics For New Chemical Entity
India's Shilpa Medicare jumps after qtrly profit rise
Brief: Shilpa Medicare Files Rotigotine Transdermal Patch ANDA To USFDA
Brief: Shilpa Medicare Dec-Quarter Consol Net PAT 445.8 Million Rupees
Brief: Shilpa Medicare, mAbTree Biologics Get FDA Orphan Drug Designation
Brief: Shilpa Medicare Restrained From Manufacturing And Exporting Ruxolitinib
Brief: Shilpa Medicare Receives Initial Authorization From Europe For Rotigotine Patch Marketing